Uropathogenic <i>Escherichia coli</i> endeavors: an insight into the characteristic features, resistance mechanism, and treatment choice

dc.contributor.author Arafi, Vahid
dc.contributor.author Hasani, Alka
dc.contributor.author Sadeghi, Javid
dc.contributor.author Varshochi, Mojtaba
dc.contributor.author Poortahmasebi, Vahdat
dc.contributor.author Hasani, Akbar
dc.contributor.author Hasani, Roqaiyeh
dc.date.accessioned 2024-05-25T11:38:04Z
dc.date.available 2024-05-25T11:38:04Z
dc.date.issued 2023
dc.description Hasani, Alka/0000-0001-6648-0893 en_US
dc.description.abstract Uropathogenic Escherichia coli (UPEC) are the strains diverted from the intestinal status and account mainly for uropathogenicity. This pathotype has gained specifications in structure and virulence to turn into a competent uropathogenic organism. Biofilm formation and antibiotic resistance play an important role in the organism's persistence in the urinary tract. Increased consumption of carbapenem prescribed for multidrug-resistant (MDR) and Extended-spectrum-beta lactamase (ESBL)-producing UPECs, has added to the expansion of resistance. The World Health Organization (WHO) and Centre for Disease Control (CDC) placed the Carbapenem-resistant Enterobacteriaceae (CRE) on their treatment priority lists. Understanding both patterns of pathogenicity, and multiple drug resistance may provide guidance for the rational use of anti-bacterial agents in the clinic. Developing an effective vaccine, adherence-inhibiting compounds, cranberry juice, and probiotics are non-antibiotical approaches proposed for the treatment of drug-resistant UTIs. We aimed to review the distinguishing characteristics, current therapeutic options and promising non-antibiotical approaches against ESBL-producing and CRE UPECs. en_US
dc.description.sponsorship Research Center of Infectious Dis-eases and Tropical Diseases [66994] en_US
dc.description.sponsorship Authors are thankful to the Research Center of Infectious Dis-eases and Tropical Diseases for funding this project (Research Project No. 66994). The funding body had no role in the study design, data collection, analysis and interpretation of results, writing the manuscript or decision to publish this paper. en_US
dc.identifier.citationcount 1
dc.identifier.doi 10.1007/s00203-023-03553-5
dc.identifier.issn 0302-8933
dc.identifier.issn 1432-072X
dc.identifier.scopus 2-s2.0-85158136478
dc.identifier.uri https://doi.org/10.1007/s00203-023-03553-5
dc.identifier.uri https://hdl.handle.net/20.500.14517/1243
dc.language.iso en
dc.publisher Springer en_US
dc.rights info:eu-repo/semantics/closedAccess en_US
dc.subject Uropathogenic Escherichia coli en_US
dc.subject Therapeutic en_US
dc.subject beta-lactamase en_US
dc.subject Carbapenem en_US
dc.subject Virulence en_US
dc.subject Vaccine en_US
dc.title Uropathogenic <i>Escherichia coli</i> endeavors: an insight into the characteristic features, resistance mechanism, and treatment choice en_US
dc.type Review en_US
dspace.entity.type Publication
gdc.author.id Hasani, Alka/0000-0001-6648-0893
gdc.author.scopusid 58237465500
gdc.author.scopusid 16303715400
gdc.author.scopusid 55846121100
gdc.author.scopusid 16403808800
gdc.author.scopusid 55755433500
gdc.author.scopusid 45461160600
gdc.author.scopusid 45461160600
gdc.coar.access metadata only access
gdc.coar.type text::review
gdc.description.department Okan University en_US
gdc.description.departmenttemp [Arafi, Vahid; Hasani, Alka] Tabriz Univ Med Sci, Infect & Trop Dis Res Ctr, Tabriz, Iran; [Arafi, Vahid; Hasani, Alka; Sadeghi, Javid; Poortahmasebi, Vahdat] Tabriz Univ Med Sci, Fac Med, Dept Bacteriol & Virol, Tabriz, Iran; [Hasani, Alka] Tabriz Univ Med Sci, Fac Med Res & Treatment Ctr, Clin Res Dev Unit, Tabriz, Iran; [Varshochi, Mojtaba] Tabriz Univ Med Sci, Fac Med, Dept Infect Dis & Trop Med, Tabriz, Iran; [Hasani, Akbar] Tabriz Univ Med Sci, Fac Med, Dept Clin Biochem & Lab Sci, Tabriz, Iran; [Hasani, Roqaiyeh] Istanbul Okan Univ, TR-34959 Tuzla, Istanbul, Turkiye en_US
gdc.description.issue 6 en_US
gdc.description.publicationcategory Diğer en_US
gdc.description.scopusquality Q3
gdc.description.volume 205 en_US
gdc.description.wosquality Q3
gdc.identifier.pmid 37156886
gdc.identifier.wos WOS:000984692800001
gdc.index.type WoS
gdc.index.type Scopus
gdc.index.type PubMed
gdc.scopus.citedcount 4
gdc.wos.citedcount 5

Files